DNA damage can cause (and result from) oxidative stress and mitochondrial impairment, both of which are implicated in the pathogenesis of Parkinson's disease (PD). We therefore examined the role of mitochondrial DNA (mtDNA) damage in human postmortem brain tissue and in in vivo and in vitro models of PD, using a newly adapted histochemical assay for abasic sites and a quantitative polymerase chain reaction (QPCR)-based assay. We identified the molecular identity of mtDNA damage to be apurinic/apyrimidinic (abasic) sites in substantia nigra dopamine neurons, but not in cortical neurons from postmortem PD specimens. To model the systemic mitochondrial impairment of PD, rats were exposed to the pesticide rotenone. After rotenone treatment that does not cause neurodegeneration, abasic sites were visualized in nigral neurons, but not in cortex. Using a QPCRbased assay, a single rotenone dose induced mtDNA damage in midbrain neurons, but not in cortical neurons; similar results were obtained in vitro in cultured neurons. Importantly, these results indicate that mtDNA damage is detectable prior to any signs of degeneration -and is produced selectively in midbrain neurons under conditions of mitochondrial impairment. The selective vulnerability of midbrain neurons to mtDNA damage was not due to differential effects of rotenone on complex I since rotenone suppressed respiration equally in midbrain and cortical neurons. However, in response to complex I inhibition, midbrain neurons produced more mitochondrial H 2 O 2 than cortical neurons. We report selective mtDNA damage as a molecular marker of vulnerable nigral neurons in PD and suggest that this may result from intrinsic differences in how these neurons respond to complex I defects. Further, the persistence of abasic sites suggests an ineffective base excision repair response in PD.
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Introduction
Parkinson's disease (PD) is the most common neurodegenerative movement disorder. A central pathological hallmark of PD is the loss of dopamine neurons in the substantia nigra pars compacta. These dopaminergic neurons are required for proper motor function, and their loss is associated with tremor, rigidity, bradykinesia and postural instability. The initial underlying mechanisms that trigger neurodegeneration in PD are complex and not completely understood. To date, treatments are only symptomatic; they do not alter the inexorable progression of the disease. Even with expert treatment, PD patients typically deteriorate over time and endure considerable motor and cognitive disability in the years after diagnosis.
High levels of reactive oxygen species (ROS) are an intrinsic property of the vulnerable subpopulation of ventral midbrain (VMB) dopaminergic neurons (Guzman et al., 2010) . Despite strong evidence that oxidative damage to proteins and lipids is a contributing factor in PD pathogenesis (Mariani et al., 2005; Sherer and Greenamyre, 2005; Cardoso et al., 2005; Jenner, 1998) , very little is known about DNA damage in PD (Sanders and Greenamyre, 2013) . DNA damage is defined as a modification that either alters its coding properties or interferes with normal cell metabolism (Lindahl, 1993; Rao, 1993) , and many different forms of DNA damage can be generated by both normal cellular functions and exogenous stressors (Friedberg et al., 2006) . DNA damage is distinct from DNA mutations, which are changes in the base sequence of the DNA. Higher levels of mitochondrial mutations have been found in dopaminergic neurons in the substantia nigra of PD patients relative Neurobiology of Disease 70 (2014) 214-223 
